How Low Should LDL-C Go? The Role of Non-Statin Therapy in Management of Blood Cholesterol

<p>Hannah Poppen, PharmD (<a href='https://twitter.com/PoppenPharmD'>@PoppenPharmD</a>) reviews guideline recommendations for management of blood cholesterol, describes the risks and benefits associated with adjunct non-statin therapy and identifies patient-specific characteristics in which PCSK9 inhibitor therapy should be considered.</p> <p>For more pharmacy content, follow Mayo Clinic Pharmacy Residency Programs <a href='https://twitter.com/MayoPharmRes'>@MayoPharmRes</a> or the host, Garrett E. Schramm, Pharm.D., <a href='https://twitter.com/garrett_schramm'>@garrett_schramm</a> on Twitter!</p> <p>You can also connect with the Mayo Clinic’s School of Continuous Professional Development online at <a href='https://ce.mayo.edu/'>https://ce.mayo.edu/</a> or on Twitter <a href='https://twitter.com/MayoMedEd'>@MayoMedEd</a>. </p>